Bayer’s Bold Shake‑Up: 12,000 Jobs, 2.6B Euro Savings, and a Big Restructuring Plan
Big news from German powerhouse Bayer: the company is slashing roughly 12,000 positions—about one in every ten of its 118,200 roles—after the mega‑merger with Mon‑ants. The aim? To trim costs by a whopping 2.6 billion euros (S$4.1 billion) a year starting from 2022.
Why the Reckoning?
- The Mon‑ants takeover was a record‑breaking $63 billion deal (S$86.3 billion) for July 2022.
- But just two months later, a U.S. court slammed Bayer with multi‑million dollar damages for failing to warn users about cancer risks linked to its herbicide Roundup.
- Investors reacted quietly—shares dipped 0.72% to 63.77 € as the DAX stayed flat.
Targeted Cuts & Business Focus
Bayer’s strategy is laser‑focused: ditch the animal‑health segment and streamline its core businesses—pharmaceuticals, consumer health, and crop science.
- Crop science will absorb most of the cuts: 4,100 jobs will disappear.
- Other potential divestments: the Coppertone sun‑care brand and Dr. Scholl’s foot‑care line.
- The restructuring is slated for completion by the end of 2021.
“These changes are necessary to reinforce Bayer’s performance and agility,” announced Chairman Werner Baumann. “We are poised to fully harness the growth potential across our businesses.”
Glyphosate Gloom & Legal Maelstrom
US & European campaigners blame glyphosate—the active ingredient in Roundup—for cancer, while Bayer points to studies that show no link. In October, a San Francisco judge trimmed a jury verdict’s damage award from $289 million to $78 million.
- Last month, Bayer’s U.S. subsidiary faced 9,300 glyphosate‑related lawsuits.
- Baumann remains confident but acknowledges that more suits could arrive, prompting Bayer to “defend itself with all means available.”
In short, Bayer is cleaning house, tightening its belt, and staying resilient—while the glyphosate debate keeps a pulse on its future.
